Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases.
Uea-Areewongsa P, Pinpathomrat N, Ongarj J, Sophonmanee R, Seepathomnarong P, Seeyankem B, Surasombatpattana S, Intapiboon P. Uea-Areewongsa P, et al. Asian Pac J Allergy Immunol. 2023 Jan 3. doi: 10.12932/AP-280722-1420. Online ahead of print. Asian Pac J Allergy Immunol. 2023. PMID: 36592166 Free article.
Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report.
Intapiboon P, Pinpathomrat N, Juthong S, Uea-Areewongsa P, Ongarj J, Siripaitoon B. Intapiboon P, et al. Among authors: uea areewongsa p. Vaccines (Basel). 2023 Feb 24;11(3):537. doi: 10.3390/vaccines11030537. Vaccines (Basel). 2023. PMID: 36992120 Free PMC article.
Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
Mahakkanukrauh A, Chaiamnuay S, Koolvisoot A, Kitamnuayphong T, Manavathongchai S, Osiri M, Louthrenoo W, Uea-Areewongsa P, Ahn K, Jung N, Kim M, Lee S, Kim H, Kim S. Mahakkanukrauh A, et al. Among authors: uea areewongsa p. Immunotherapy. 2023 Oct;15(14):1143-1155. doi: 10.2217/imt-2022-0290. Epub 2023 Aug 17. Immunotherapy. 2023. PMID: 37589164 Free article.
2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Louthrenoo W, Kasitanon N, Katchamart W, Aiewruengsurat D, Chevaisrakul P, Chiowchanwisawakit P, Dechanuwong P, Hanvivadhanakul P, Mahakkanukrauh A, Manavathongchai S, Muangchan C, Narongroeknawin P, Phumethum V, Siripaitoon B, Suesuwan A, Suwannaroj S, Uea-Areewongsa P, Ukritchon S, Asavatanabodee P, Koolvisoot A, Nanagara R, Totemchokchyakarn K, Nuntirooj K, Kitumnuaypong T. Louthrenoo W, et al. Among authors: uea areewongsa p. Int J Rheum Dis. 2017 Sep;20(9):1166-1184. doi: 10.1111/1756-185X.13130. Epub 2017 Jul 21. Int J Rheum Dis. 2017. PMID: 28730640 Review.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.